Vor Biopharma is a pre-revenue, cash-burning biotech whose value rests on a single pipeline asset (telitacicept) licensed from RemeGen, with large analyst upside offset by below-floor quality and a 63% drawdown.
Thesis pillars
- Single Asset Pipeline Concentration↑Improving
- Cash Burn No Revenue→Stable
- Licensor Counterparty Dependence↑Improving
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Mar 30, 2026
Vor Biopharma Inc. (VOR) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $20.65: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 4.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality.
Vor Bio is a clinical-stage biopharmaceutical company developing telitacicept, a fusion-protein therapy licensed from RemeGen in June 2025 outside Greater China, running global Phase 3 trials in myasthenia gravis and Sjogren's disease. Pre-revenue, Vor Bio paid RemeGen a $125... Read more
Sell if holding. Engine safety override at $20.65: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 4.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.8/10, moderate confidence.
Passes 6/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Vor Biopharma Inc.
About Vor Biopharma Inc.
Vor Bio's lead and only clinical asset, telitacicept, is already approved in China for systemic lupus erythematosus, rheumatoid arthritis, and generalized myasthenia gravis (gMG), and the FDA granted the therapy Fast Track Designation for Sjogren's disease (SjD) in March 2024 after clearing the IND in January 2024. The company is now running global Phase 3 trials in gMG and SjD across the United States, Europe, South America, and Asia, with SjD's first patient dosed in March 2026.
Vor Bio generates no product revenue; it in-licensed telitacicept from RemeGen in June 2025 for all territories outside Greater China, paying a $125 million upfront fee -- $45 million in cash plus an $80 million warrant -- and owes RemeGen up to $330 million in regulatory milestones, up to $3.775 billion in sales milestones, and tiered royalties ranging from high single-digit to mid-teen percentages of net sales. Vor Bio is responsible for development, regulatory, and commercialization costs in its licensed territory, while RemeGen retains rights and continues its own trials in Greater China. The company relies on third-party contract manufacturers for clinical supply of telitacicept and does not yet have long-term manufacturing agreements in place. In the crowded autoimmune-disease field, Vor Bio competes against fusion-protein and biologic developers including Amgen and argenx, among others already marketed or in development.
Show full overview
Vor Bio's valuation rests on a single asset: the 10-K states plainly that the company is substantially dependent on telitacicept's success, with no other clinical or commercial program to fall back on. That dependence is compounded by a data-control gap: Vor Bio's Phase 3 program partly relies on trial data RemeGen generates and controls in China, and Vor Bio has no authority over those trials or their reporting to Chinese regulators, leaving U.S. and European outcomes partly dependent on a partner's execution. The company's September 2025 1-for-20 reverse stock split, disclosed alongside $455.2 million in cash meant to fund operations into early 2029, underscores the execution risk already priced in ahead of the SjD and gMG Phase 3 readouts.
See also: Healthcare · Biotechnology
From Vor Biopharma Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — Vor Biopharma Inc.
Latest news
- NEWS Vor Bio Announces Final Two-Year Results from Phase 3 TELIGAN Trial of Telitacicept in IgA Nephropathy — fiscal.ai Oct 22, 2026 positive
- NEWS Vor Bio Announces Final Two-Year Results From Phase 3 TELIGAN Trial Evaluating Telitacicept In Adults With Iga Nephropat — benzinga Oct 22, 2026 neutral
- NEWS William Blair Upgrades Vor Biopharma Inc. to Buy — fiscal.ai Oct 21, 2026 positive
- NEWS William Blair Initiates Coverage On Vor Biopharma with Outperform Rating — benzinga Oct 21, 2026 positive
- NEWS Vor Bio Announces Data Phase 3 Trial Of Telitacicept By Its RemeGen Partner Demonstrates Over 95% Participants Achieved — benzinga Sep 29, 2026 positive
Generated 2026-10-29T11:08:52Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinetelitacicept10-K Item 1A: 'We are substantially dependent on the success of our lead product candidate, telitacicept.'
- HIGHcounterpartyRemeGen10-K Item 1A: 'We have no control over the conduct and timing of, ... the trials that RemeGen is conducting for telitacicept.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $20.65: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 4.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $19.20. Score 5.8/10, moderate confidence.
Analyst target: $33.93 (+64.3% upside). Prior stop was $19.20. Stop-loss: $19.20.
Concentration risk — Pipeline: telitacicept; Concentration risk — Counterparty: RemeGen; Quality below floor (1.5 < 4.0).
Vor Biopharma Inc. trades at a P/E of 0.1 (forward -5.6). TrendMatrix value score: 9.4/10. Verdict: Sell.
13 analysts cover VOR with a consensus score of 4.2/5. Average price target: $39.
What does Vor Biopharma Inc. do?Vor Bio is a clinical-stage biopharmaceutical company developing telitacicept, a fusion-protein therapy licensed from...
Vor Bio is a clinical-stage biopharmaceutical company developing telitacicept, a fusion-protein therapy licensed from RemeGen in June 2025 outside Greater China, running global Phase 3 trials in myasthenia gravis and Sjogren's disease. Pre-revenue, Vor Bio paid RemeGen a $125 million upfront fee and owes milestone and royalty payments on future sales. Telitacicept is approved in China for lupus, rheumatoid arthritis, and myasthenia gravis.